Compare FULT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULT | ADMA |
|---|---|---|
| Founded | 1882 | 2004 |
| Country | United States | United States |
| Employees | 3400 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.6B |
| IPO Year | N/A | 2012 |
| Metric | FULT | ADMA |
|---|---|---|
| Price | $20.74 | $9.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $21.40 | ★ $32.00 |
| AVG Volume (30 Days) | 2.1M | ★ 8.8M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $6.39 | $27.46 |
| Revenue Next Year | $5.52 | $22.11 |
| P/E Ratio | ★ $10.58 | $15.48 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $14.70 | $7.21 |
| 52 Week High | $22.99 | $25.67 |
| Indicator | FULT | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 25.88 |
| Support Level | $19.05 | $7.21 |
| Resistance Level | $21.01 | $16.44 |
| Average True Range (ATR) | 0.48 | 1.07 |
| MACD | 0.16 | -0.23 |
| Stochastic Oscillator | 91.78 | 23.31 |
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.